



# Essai Clinique

Généré le 04 mai 2024 à partir de

Titre	Étude pancanadienne de surveillance moléculaire du myélome multiple menée par l'Institut de recherche Terry Fox
Protocole ID	NCI M4
ClinicalTrials.gov ID	<a href="#">NCT03421132</a>
Type(s) de cancer	Myélome
Phase	Autres
Stade	Myélome multiple
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur principal	Dr Richard Leblanc
Coordonnateur	Nathalie Lachapelle 514-252-3400 poste 4471
Statut	Actif en recrutement
Date d'activation	11-09-2018
But étude	The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.
Critères d'éligibilité	<ul style="list-style-type: none"><li>• Ability to give informed consent</li><li>• Diagnosed with active multiple myeloma</li><li>• Consented to participation in Myeloma Canada Research Network (MCRN) database project</li><li>• Previously untreated and eligible for autologous stem-cell transplantation (ASCT)</li></ul>
Critères d'exclusion	<ul style="list-style-type: none"><li>• Ineligible for ASCT</li><li>• Does not consent to participate in MCRN database project</li></ul>